Led · Series A · Oct 2025

Amprologix, a spin-out from the University of Plymouth, focuses on discovering and developing new antibiotics aimed at hard-to-treat, antimicrobial-resistant infections. Its lead asset, epidermicin NI01, targets Methicillin-resistant Staphylococcus aureus (MRSA) and has shown daily-dose efficacy comparable to current standard wound-care treatments. The company plans to complete pre-clinical work on NI01 and enter Phase I human trials in 2026. In parallel, Amprologix is advancing TOBRADERM, a £1 million R&D project supported by Innovate UK’s Biomedical Catalyst programme, and is progressing a separate programme for preventing and treating Clostridioides difficile infections. Financially, the company has just secured £740,000 in pre-Series A capital and intends to raise a £5 million Series A round to fund first-in-human studies and broaden its drug pipeline. Frontier IP Group plc holds an equity stake in the company. The recent investment also strengthens the board with the addition of Dr. Rita Dobmeyer from Plutus Investment Group.

Led · Seed · Jan 2023

MPC Therapeutics is a Swiss biotechnology company spun off from the University of Geneva in 2018 that develops small molecules to modulate mitochondrial function and trigger cellular reprogramming. Its proprietary compounds specifically inhibit the Mitochondrial Pyruvate Carrier (MPC) and were discovered and optimized based on the work of Prof. Jean‑Claude Martinou. The lead program is a small‑molecule adjuvant designed to improve the performance and durability of CAR‑T cell therapies and has shown dramatic survival improvements in multiple preclinical cancer models. The company closed a CHF 1.5 million seed round to advance its lead compound toward clinical trials and to expand into new therapeutic applications. MPC Therapeutics plans to enter the clinic in 2024 and also intends to position its molecules as potential treatments for alopecia by promoting stem cell proliferation. The financing will support IND‑enabling work and early development of the T‑cell therapy adjuvant program.